Navigation Links
Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
Date:5/27/2008

" said Gordon Mills, M.D., Ph.D., director of M. D. Anderson's Kleberg Center for Molecular Markers and chair of the Department of Systems Biology.

"We have been developing collaborative studies with industry leaders to bring novel technological approaches to achieve the mission of personalizing medicine at the Kleberg Center for Molecular Markers," said Rahul Mitra, Ph.D., associate director of the Kleberg Center.

About LNATM

LNAs are a class of nucleotide analogues that bind very strongly to RNA and DNA targets. By including LNAs in detection probes, it is possible to design very specific high-affinity detection assays for small RNA targets like miRNAs, which otherwise is not possible using standard DNA based detection probes.

About miRNA

microRNAs (miRNAs) are a novel class of regulatory RNA molecules with surprisingly widespread effects on gene regulation. Although recently identified as a class of molecules, initial studies indicate that miRNAs may regulate as much as 1/3 of all genes in the genome, thus comprising an up till now hidden level of regulation. Interestingly, miRNAs have already been found to play important roles in several types of cancers and in processes involved in cellular differentiation. In the cell, miRNAs are found in form of single-stranded RNA molecules, which are typically 20-25 nucleotides long in their active form.

About breast cancer

Breast cancer is one of the most prevalent cancers estimated to world wide affect approximately 1 million women annually. The standard diagnostics for breast cancer is based on histology as well as molecular markers such as Estrogen-receptor (ER) and Progesterone-receptor (PR) protein status. The primary treatment for breast cancer is surgery and radiation, followed by adjuvant chemotherapy. However, 70-80% of patients receiving this treatment will survive without it, and therefore there is a need for diagnostic tests that help patients and doctors decide
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
4. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
5. Allegheny General Hospital Performs First Liver Transplant
6. Research Team Clones Genes Responsible for Amino Acid Absorption
7. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
8. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
11. Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
(Date:8/21/2014)... 21, 2014   Memorial Hermann Health System and ... today announced a new partnership to provide a new level ... care centers in the greater Houston ... become the exclusive provider of professional breast radiology services for ... Memorial City, The Woodlands , Northeast, Southwest ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
(Date:8/23/2014)... New York, New York (PRWEB) August 23, 2014 ... ( http://www.consumerinjurylawyers.com/wright-conserve-hip-replacement.html ) filed on behalf of ... in the Conserve hip replacement line continue to ... District of Georgia, Bernstein Liebhard LLP reports. According ... has established a bellwether trial program that would ...
(Date:8/23/2014)... NY (PRWEB) August 23, 2014 On ... reported on a data breach suffered by Community ... saw the compromise of 4.5 million records containing Personally ... security numbers. According to Mandiant, who was engaged to ... from an advanced group of cyber attackers based ...
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, August 18th ... of water for commercial and industrial properties. This was ... Archworks, LLC in Carmel, California. , This is a ... district in the State of California has approved this technology ... this time can now be used as a sole source ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut ... ProIntro Vol.3, a customizable title tool for FCPX ... by dragging ProIntro Vol.3 in their timeline" says Christina Austin, ... time saver and i think our users will agree" , ... titles made with Final Cut Pro X users in mind. ...
(Date:8/23/2014)... Dealing with a drug or alcohol substance abuse is never ... child. Adolescent addiction has been an important issue among young ... helpline is now providing a valuable resource for teenage ... addiction recovery center. , The Troubled Teens Atlanta helpline was ... By calling (404) 975-2762, parents and their teens can speak ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2
... cancer are at higher risk of developing diabetes or diabetes ... block the production or action of male hormones that can ... new study on the second-most common cancer in men are ... in Boston. "These patients may benefit from counseling, screening ...
... (Hamilton, ON) June 4, 2011 - Additional radiation treatment ... recurring in women with early breast cancer who have ... new study found. The results will be presented Monday, ... Society of Clinical Oncology. "These results are ...
... a lot of sugar to stay alive. In fact, where normal, ... of oxygen, cancerous cells use virtually no oxygen and a lot ... now, reporting in the May 27 issue of Cell , ... that this so-called Warburg effect is controlled. "It turns ...
... -- ASCO Abstract #10504. Contrary to what many oncologists had ... reduce the effectiveness of the breast cancer drug Herceptin, according ... North Central Cancer Research Group (NCCTG) investigators. The study, ... NCCTG N9831 clinical trial, found that patients with HER2-positive breast ...
... is the most lethal type of skin cancer, the results of ... immune-boosting drug Interleukin-2 can improve response rate and progression-free survival. ... June 2 issue of New England Journal of Medicine . ... one of the first in all cancers to show clinical benefit ...
... Amanda Gardner HealthDay Reporter , THURSDAY, June ... used to treat high blood pressure doesn,t boost the ... health authorities announced Thursday. The drugs are known ... telmisartan (Micardis), losartan (Cozaar), valsartan (Diovan) and candesartan (Atacand). ...
Cached Medicine News:Health News:Hormone deprivation therapy for prostate cancer may raise diabetes risk 2Health News:Breast cancer surgery patients benefit from adding radiation therapy 2Health News:Understanding cancer energetics 2Health News:Mayo Clinic, NCCTG find no tie between PTEN and response to breast cancer drug 2Health News:Vaccine first to show improved survival rates for metastatic melanoma 2Health News:Vaccine first to show improved survival rates for metastatic melanoma 3Health News:Popular Blood Pressure Meds Not Linked to Cancer, FDA Says 2
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: